<?xml version="1.0" encoding="UTF-8" ?>
			<?xml-stylesheet href="/rss/rss2html.xsl" type="text/xsl" media="screen"?>
			<rss version="2.0" xmlns:alacra="http://www.alacra.com" xmlns:ccbn="http://www.alacra.com/ccbn" xmlns:cs="http://www.alacra.com/cs" xmlns:sdc="http://www.alacra.com/sdc" xmlns:newstex="http://www.alacra.com/newstex" ><channel><title>Pfizer Inc. RSS Research Feed - Subscribe Today - AlacraStore.com</title>
<description>Pfizer Inc.</description>
<link>http://www.alacrastore.com/company-snapshot/Pfizer_Inc-1013167</link>
<lastBuildDate>Friday, July 25, 2008 11:22:33 PM</lastBuildDate>
<alacra:xlsid>1013167</alacra:xlsid>
<alacra:company>Pfizer Inc.</alacra:company>
<language>en</language>
<generator>AlacraStore RSS Builder 1.0</generator>
<ttl>30</ttl>
<item><link>http://www.alacrastore.com/storecontent/cs/4463</link><guid isPermaLink="false">cs/4463</guid><cs:index_mode xmlns:cs="http://www.alacra.com/cs">norm</cs:index_mode><description> Health Care Costs: High Fever Still â–ª Health benefit costs increased ##.#% in ####, the largest increase since ####, and are expected to rise in the ##% range in ####â–ª Large health cost increases in a weakening economy have...</description><cs:csid xmlns:cs="http://www.alacra.com/cs">4463</cs:csid><title>Health Care Costs: High Fever Still</title><cs:wcnum xmlns:cs="http://www.alacra.com/cs">1822</cs:wcnum><cs:ft xmlns:cs="http://www.alacra.com/cs">Yes</cs:ft><cs:wc xmlns:cs="http://www.alacra.com/cs">D</cs:wc><cs:type xmlns:cs="http://www.alacra.com/cs">0</cs:type><cs:typew xmlns:cs="http://www.alacra.com/cs">Article</cs:typew><cs:company xmlns:cs="http://www.alacra.com/cs">780</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">45</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">434</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">333</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">563</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">451</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">782</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">506</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">500</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">640</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">880</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">332</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">531</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">2056</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">562</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">47</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">20</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">441</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">422</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">892</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">21</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">2055</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">22</cs:company><cs:company xmlns:cs="http://www.alacra.com/cs">519</cs:company><cs:DS xmlns:cs="http://www.alacra.com/cs">corp</cs:DS><cs:geo xmlns:cs="http://www.alacra.com/cs">1</cs:geo><cs:industry xmlns:cs="http://www.alacra.com/cs">10</cs:industry><cs:industry xmlns:cs="http://www.alacra.com/cs">58</cs:industry><cs:industry xmlns:cs="http://www.alacra.com/cs">39</cs:industry><cs:cstopic xmlns:cs="http://www.alacra.com/cs">34</cs:cstopic><cs:tw xmlns:cs="http://www.alacra.com/cs">Companies with Convertibles</cs:tw><cs:cstopic xmlns:cs="http://www.alacra.com/cs">14</cs:cstopic><cs:tw xmlns:cs="http://www.alacra.com/cs">Regulatory Matters</cs:tw><cs:abstract xmlns:cs="http://www.alacra.com/cs">Health benefit costs increased 14.7% in 2002, the largest increase since 1990, and are expected to rise in the 14% range in 2003. Escalating health care costs remain a particular threat for mature, unionized cyclicals.</cs:abstract><pubDate>7/25/2008 4:10:14 PM</pubDate><cs:price xmlns:cs="http://www.alacra.com/cs">150</cs:price><cs:docid xmlns:cs="http://www.alacra.com/cs">4463</cs:docid><category>Credit &amp; Investment Research</category><alacra:ip>CreditSights</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/B1885796</link><guid isPermaLink="false">ccbn/B1885796</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Pleased with financial performance, especially at this time of great uncertainty in world economy and capital markets, and significant challenges in industry. ...

</description><pubDate>7/24/2008 6:18:26 AM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Pfizer</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">106.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Edited</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Q2 2008 Pfizer Earnings Conference Call Summary</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">PFE</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Q2 2008 Pfizer Earnings Conference Call Summary</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Brief</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">B1885796</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1885796</link><guid isPermaLink="false">ccbn/T1885796</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>... - Pfizer -  SVP, IR Good morning and thank you for joining us today to review our second-quarter #### performance. I'm here where Jeff Kindler,  Chairman and CEO; Frank D'Amelio, Chief Financial Officer, and other members of our senior management team. The financial charts that will be presented on this call can be viewed on our home page at www.Pfizer.com in the Investor Presentations tab by clicking on the link, Quarterly Corporate Performance Second Quarter ####. We know this is a busy day for many of you, and our conference call will last an hour, and we will end at noon. As we would like to hear from as many of you as we can in this time, we ask that you limit your questions to just one question please. Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ...

</description><pubDate>7/23/2008 1:12:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Pfizer</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">106.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Q2 2008 Pfizer Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">PFE</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Q2 2008 Pfizer Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1885796</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/ACT-0001-26863734</link><guid isPermaLink="false">newstex/ACT-0001-26863734</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jul. ##, #### (Action Economics delivered by Newstex) -- 
Corporate earnings Wed include GlaxoSmithKline, Pfizer, Boeing and ConocoPhillipsU.S. Fed's Beige Book likely to indicate slowing economy but elevated price pressures U.S. calendar...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04017000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04017002</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04005012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">06000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">06001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">06001002</newstex:cat><pubDate>7/23/2008 9:08:32 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18005000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Action Economics A.M.</newstex:Publication><title>Overnight Action Bullets</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">ACT-0001-26863734</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">BOEING CO</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">CONOCOPHILLIPS</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">BA</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">COP</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/ACT-0001-26863535</link><guid isPermaLink="false">newstex/ACT-0001-26863535</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jul. ##, #### (Action Economics delivered by Newstex) --  Treasury Market Outlook: Treasuries sunk lower overnight, with yields climbing some # bps to # bps, as stocks post solid gains and the dollar firms. Further weakness in oil futures...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04009000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04009004</newstex:cat><pubDate>7/23/2008 9:08:31 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18003000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Action Economics Alerts</newstex:Publication><title>Treasury Market Outlook: Treasuries sunk lower overnight</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">ACT-0001-26863535</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">BP</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">YAHOO INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">BP'U</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">YHOO</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-26695480</link><guid isPermaLink="false">newstex/BW-0001-26695480</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jul. ##, #### (Business Wire) --  Research and Markets (http://www.researchandmarkets.com/research/c#####/netherlands_pharma) has announced the addition of the "Netherlands Pharmaceuticals and Healthcare Report Q# ####" report to their...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04017000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04017002</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>7/16/2008 7:07:18 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18005000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18002000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002018</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><title>Research and Markets: In February 2008, a Dutch Court Ruled against Us Drug-Maker Pfizer in a Court Case Regarding the Patent on Atorvastatin</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-26695480</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-26567987</link><guid isPermaLink="false">newstex/PRN-0005-26567987</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> SHANGHAI, China, Jul. ##, #### (Xinhua-PRNewswire delivered by Newstex) -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04006000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">09015000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13002005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><pubDate>7/10/2008 9:08:08 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18007000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19001000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002009</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002013</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002004</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-26567987</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">CITY CAPITAL CORP</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GENENTECH INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">MORGAN STANLEY</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">CTCC</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">DNA</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">MS</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-26551664</link><guid isPermaLink="false">newstex/PRN-0005-26551664</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jul. #, #### (PR Newswire delivered by Newstex) -- In the news release, Chantix Blamed for Suicide in Lawsuit Against Pfizer Filed by Cory Watson Crowder&amp; DeGaris, issued earlier today by Cory Watson Crowder&amp; DeGaris over PR Newswire,...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">14000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">14005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016027</newstex:cat><pubDate>7/9/2008 7:06:03 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18014000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002014</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>/C O R R E C T I O N -- Cory Watson Crowder &amp; DeGaris/</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-26551664</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-26548871</link><guid isPermaLink="false">newstex/PRN-0005-26548871</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> BIRMINGHAM, Ala., Jul. #, #### (PRNewswire delivered by Newstex) -- A lawsuit charges pharmaceutical giant Pfizer was motivated by greed when it failed to warn the public of potentially deadly side-effects associated with its popular...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">14000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">14005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016027</newstex:cat><pubDate>7/9/2008 5:06:06 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18014000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Chantix Blamed for Suicide in Lawsuit Against Pfizer Filed by Cory Watson Crowder &amp; DeGaris</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-26548871</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-26340240</link><guid isPermaLink="false">newstex/BW-0001-26340240</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jun. ##, #### (Business Wire) --  Global drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FSE: PSI) today announced that Dr. Paul Ashton, Managing Director, will ring the NASDAQ Stock Market Closing Bell on Tuesday, July...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>6/30/2008 2:21:58 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002013</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><title>pSivida Managing Director to Ring the NASDAQ Stock Market Closing Bell on Tuesday, July 1</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-26340240</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PSIVIDA LTD</newstex:index_entry_company><newstex:index_entry_person xmlns:newstex="http://www.alacra.com/newstex">Paul Ashton</newstex:index_entry_person><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PSDV</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-26255967</link><guid isPermaLink="false">newstex/BW-0001-26255967</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jun. ##, #### (Business Wire) --  pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FSE:PSI) today announced that the symbol for its common stock, traded on NASDAQ has returned to PSDV today. 
About pSivida Corp. pSivida is a global drug delivery...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>6/26/2008 10:06:44 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><title>pSivida Announces Symbol Change back to PSDV</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-26255967</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/MW-0001-26186187</link><guid isPermaLink="false">newstex/MW-0001-26186187</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> COLOGNE, GERMANY, Jun. ##, #### (Marketwire delivered by Newstex) -- COLOGNE, GERMANY -- (MARKET WIRE) -- ##/##/## --  DIREVO Biotech AG, a world-wide leader in high throughput protein and strain engineering, announced today receipt...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04018000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016031</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002008</newstex:cat><pubDate>6/24/2008 3:06:25 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Marketwire</newstex:Publication><title>DIREVO Receives Broad European Patent Protection for its Protease Optimization Platform</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">MW-0001-26186187</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/HUG-0001-26185195</link><guid isPermaLink="false">newstex/HUG-0001-26185195</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jun. ##, #### (Hugin AS delivered by Newstex) --   Cologne, Germany, June  ##, ####  - DIREVO Biotech  AG, a  world-wide leader in high throughput  protein and strain engineering,  announced today receipt  of notice  from the  European...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04018000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016031</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002008</newstex:cat><pubDate>6/24/2008 3:06:24 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Hugin AS</newstex:Publication><title>DIREVO Receives Broad European Patent Protection for its Protease  Optimization Platform</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">HUG-0001-26185195</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ASTRAZENECA PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">AZN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/BW-0001-26173910</link><guid isPermaLink="false">newstex/BW-0001-26173910</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jun. ##, #### (Business Wire) --  pSivida Corp. (NASDAQ:PSDVV)(ASX:PVA)(FWB:PSI) today announced that a discussion of the implementation of the Scheme of Arrangement for pSividaaÂ€Â™s reincorporation in the US has been filed in an Open...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><pubDate>6/23/2008 3:08:24 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Business Wire</newstex:Publication><title>pSivida Discusses Reincorporation in Open Briefing Interview</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">BW-0001-26173910</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/CNG-0001-26158691</link><guid isPermaLink="false">newstex/CNG-0001-26158691</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jun. ##, #### (CompanyNewsGroup delivered by Newstex) -- BioAlliance Pharma extends its Loramyc(TM) License to China through an agreement with NovaMed (NASDAQ:NOVA)  PharmaceuticalsParis, June ##th, #### - BioAlliance Pharma SA (Euronext...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>6/23/2008 2:06:34 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18015000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002009</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002013</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002004</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002018</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002001</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Hugin Southern Europe</newstex:Publication><title>BioAlliance Pharma extends its Loramyc(TM) License to China with NovaMed Pharmaceuticals</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">CNG-0001-26158691</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">NOVAMED INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">SANOFI-AVENTIS</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">NOVA</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">SNY</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/MW-0001-26158274</link><guid isPermaLink="false">newstex/MW-0001-26158274</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> PARIS, Jun. ##, #### (Marketwire delivered by Newstex) -- PARIS -- (MARKET WIRE) -- ##/##/## --  BioAlliance Pharma extends its Loramyc(TM) License to China through an agreement with NovaMed Pharmaceuticals Paris, June ##th, #### -...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07001004</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>6/23/2008 2:06:34 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18022000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18015000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002009</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002013</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002004</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002018</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002001</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">Marketwire</newstex:Publication><title>BioAlliance Pharma extends its Loramyc(TM) License to China with NovaMed Pharmaceuticals</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">MW-0001-26158274</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">NOVAMED INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">SANOFI-AVENTIS</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">NOVA</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">SNY</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/HIN-0001-26136113</link><guid isPermaLink="false">newstex/HIN-0001-26136113</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jun. ##, #### (The Hindu Business Line delivered by Newstex) --   Sensex opened on a positive note on Monday and climbed nearly ### points from the previous close of #####, helped by short-covering and touched the intraday high of #####....</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016009</newstex:cat><pubDate>6/20/2008 7:06:35 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18011000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">The Hindu Business Line</newstex:Publication><title>Markets this week</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">HIN-0001-26136113</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">HDFC BANK LTD</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">ICICI BANK LTD</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">RELIANCE INFRASTRUCTURE LTD</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">HDB</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">IBN</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">RCTDF</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/HIN-0001-26107755</link><guid isPermaLink="false">newstex/HIN-0001-26107755</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jun. ##, #### (The Hindu Business Line delivered by Newstex) --     Consumers will   be paying more for an innovative medicine, till the generic version comes into the market.  It was a high-profile litigation destined to go down to...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016031</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016027</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016013</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002008</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">02002004</newstex:cat><pubDate>6/19/2008 6:06:35 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18018000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18014000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18020000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18015000</newstex:event><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19000000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002000</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002007</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002018</newstex:geo><newstex:geo xmlns:newstex="http://www.alacra.com/newstex">19002013</newstex:geo><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">The Hindu Business Line</newstex:Publication><title>The importance of being Lipitor</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">HIN-0001-26107755</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">DR REDDYS LABORATORIES LTD</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">GLAXOSMITHKLINE PLC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">GSK</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">RDY</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><title>Pfizer Inc acquires Tianjin Tianyao Pharm Co Ltd (pending)</title><description>CHINA - Pfizer Inc planned to merge with Tianjin Tianyao Pharmaceutical Co Ltd, a pharmaceuticals manufacturer and wholesaler.</description><pubDate>6/19/2008 5:22:43 PM</pubDate><sdc:company_cusip xmlns:sdc="http://www.alacra.com/sdc">717081</sdc:company_cusip><sdc:target_company_cusip xmlns:sdc="http://www.alacra.com/sdc">88662L</sdc:target_company_cusip><sdc:company_cusip_up xmlns:sdc="http://www.alacra.com/sdc">717081</sdc:company_cusip_up><sdc:target_company_cusip_up xmlns:sdc="http://www.alacra.com/sdc">88662L</sdc:target_company_cusip_up><sdc:company xmlns:sdc="http://www.alacra.com/sdc">Pfizer Inc</sdc:company><sdc:target_company xmlns:sdc="http://www.alacra.com/sdc">Tianjin Tianyao Pharmaceutical Co Ltd</sdc:target_company><sdc:company_up xmlns:sdc="http://www.alacra.com/sdc">Pfizer Inc</sdc:company_up><sdc:target_company_up xmlns:sdc="http://www.alacra.com/sdc">Tianjin Tianyao Pharmaceutical Co Ltd</sdc:target_company_up><link>http://www.alacrastore.com/storecontent/Thomson_M%26A/Pfizer_Inc_acquires_Tianjin_Tianyao_Pharm_Co_Ltd-1988048040</link><guid isPermaLink="false">sdc/1988048040</guid><sdc:deal xmlns:sdc="http://www.alacra.com/sdc"><sdc:deal_no>1988048040</sdc:deal_no><sdc:_copyright><sdc:value>Copyright Â© 2008, Thomson Financial, All Rights Reserved</sdc:value></sdc:_copyright><sdc:a_EXCHANGE><sdc:value>New York</sdc:value></sdc:a_EXCHANGE><sdc:a_MAINDUSTRY><sdc:value>Drugs</sdc:value></sdc:a_MAINDUSTRY><sdc:a_NATION><sdc:value>United States</sdc:value></sdc:a_NATION><sdc:a_SICDESC><sdc:value>Pharmaceutical preparations</sdc:value></sdc:a_SICDESC><sdc:a_SICPI><sdc:value>2834</sdc:value></sdc:a_SICPI><sdc:a_STATE><sdc:value>NY</sdc:value></sdc:a_STATE><sdc:a_STATELONG><sdc:value>New York</sdc:value></sdc:a_STATELONG><sdc:a_STATUS><sdc:value>Public</sdc:value></sdc:a_STATUS><sdc:a_TICKER><sdc:value>PFE</sdc:value></sdc:a_TICKER><sdc:asic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value><sdc:value sdc:p="3">5122:Drugs, drug proprietaries, and druggists' sundries</sdc:value></sdc:asic_SIC><sdc:aupsic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value><sdc:value sdc:p="3">5122:Drugs, drug proprietaries, and druggists' sundries</sdc:value></sdc:aupsic_SIC><sdc:b_EXCHANGE><sdc:value>Shanghai</sdc:value></sdc:b_EXCHANGE><sdc:b_MAINDUSTRY><sdc:value>Drugs</sdc:value></sdc:b_MAINDUSTRY><sdc:b_NATION><sdc:value>China</sdc:value></sdc:b_NATION><sdc:b_SICDESC><sdc:value>Pharmaceutical preparations</sdc:value></sdc:b_SICDESC><sdc:b_SICPI><sdc:value>2834</sdc:value></sdc:b_SICPI><sdc:b_STATE><sdc:value>FF</sdc:value></sdc:b_STATE><sdc:b_STATELONG><sdc:value>Foreign</sdc:value></sdc:b_STATELONG><sdc:b_STATUS><sdc:value>Public</sdc:value></sdc:b_STATUS><sdc:b_TICKER><sdc:value>600488</sdc:value></sdc:b_TICKER><sdc:c_ACIDGEN><sdc:value>11396001</sdc:value></sdc:c_ACIDGEN><sdc:c2up_BUSS><sdc:value>Mnfr,whl pharm</sdc:value></sdc:c2up_BUSS><sdc:c3up_BUSS><sdc:value>Mnfr,whl pharm</sdc:value></sdc:c3up_BUSS><sdc:co_DESCR><sdc:value>Unspecified</sdc:value></sdc:co_DESCR><sdc:cs_DESCR><sdc:value>Ordinary Share</sdc:value></sdc:cs_DESCR><sdc:d_TCIDGEN><sdc:value>727623002</sdc:value></sdc:d_TCIDGEN><sdc:date_lastupdate><sdc:value>Jun 19 2008</sdc:value></sdc:date_lastupdate><sdc:finbltm_BV><sdc:value>0.00000</sdc:value></sdc:finbltm_BV><sdc:finbltm_CASH><sdc:value>0.00000</sdc:value></sdc:finbltm_CASH><sdc:finbltm_CASHFLOW><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW><sdc:finbltm_CASHFLOW1><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW1><sdc:finbltm_CASHFLOW2><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW2><sdc:finbltm_CASHFLOW3><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW3><sdc:finbltm_CASHFLOW4><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW4><sdc:finbltm_CASHFLOW5><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW5><sdc:finbltm_COMEQ><sdc:value>0.00000</sdc:value></sdc:finbltm_COMEQ><sdc:finbltm_DEBTRAT><sdc:value>0.00000</sdc:value></sdc:finbltm_DEBTRAT><sdc:finbltm_DSER2><sdc:value>0.00000</sdc:value></sdc:finbltm_DSER2><sdc:finbltm_EBIT><sdc:value>0.00000</sdc:value></sdc:finbltm_EBIT><sdc:finbltm_EPS><sdc:value>0.00000</sdc:value></sdc:finbltm_EPS><sdc:finbltm_NI><sdc:value>0.00000</sdc:value></sdc:finbltm_NI><sdc:finbltm_PTINC><sdc:value>0.00000</sdc:value></sdc:finbltm_PTINC><sdc:finbltm_SALES><sdc:value>0.00000</sdc:value></sdc:finbltm_SALES><sdc:finbltm_STDEBT><sdc:value>0.00000</sdc:value></sdc:finbltm_STDEBT><sdc:finbltm_TASS><sdc:value>0.00000</sdc:value></sdc:finbltm_TASS><sdc:fiscal_ADCR><sdc:value>0.00000</sdc:value></sdc:fiscal_ADCR><sdc:fiscal_ANI><sdc:value>0.00000</sdc:value></sdc:fiscal_ANI><sdc:fiscal_APFDCR><sdc:value>0.00000</sdc:value></sdc:fiscal_APFDCR><sdc:fiscal_ASALES><sdc:value>0.00000</sdc:value></sdc:fiscal_ASALES><sdc:fiscal_ATASS><sdc:value>0.00000</sdc:value></sdc:fiscal_ATASS><sdc:fiscal_RATE><sdc:value>0.00000</sdc:value></sdc:fiscal_RATE><sdc:g_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value><sdc:value sdc:p="5">6.00000</sdc:value><sdc:value sdc:p="6">7.00000</sdc:value><sdc:value sdc:p="7">8.00000</sdc:value><sdc:value sdc:p="8">9.00000</sdc:value><sdc:value sdc:p="9">10.00000</sdc:value><sdc:value sdc:p="10">11.00000</sdc:value></sdc:g_SEQ><sdc:g_TEST><sdc:value sdc:p="0">Pfizer Inc, headquartered in</sdc:value><sdc:value sdc:p="1">New York, New York,</sdc:value><sdc:value sdc:p="2">manufactures and wholesales</sdc:value><sdc:value sdc:p="3">prescription medicines and</sdc:value><sdc:value sdc:p="4">other pharmaceuticals for</sdc:value><sdc:value sdc:p="5">humans and animals. The Group</sdc:value><sdc:value sdc:p="6">operates in three segments:</sdc:value><sdc:value sdc:p="7">Human Health segment, Consumer</sdc:value><sdc:value sdc:p="8">Healthcare segment and Animal</sdc:value><sdc:value sdc:p="9">Health segment. The company</sdc:value><sdc:value sdc:p="10">was founded in 1849.</sdc:value></sdc:g_TEST><sdc:g_business><sdc:value sdc:p="0">Pfizer Inc, headquartered in New York, New York,</sdc:value><sdc:value sdc:p="1">manufactures and wholesales prescription medicines and other</sdc:value><sdc:value sdc:p="2">pharmaceuticals for humans and animals. The Group operates</sdc:value><sdc:value sdc:p="3">in three segments: Human Health segment, Consumer Healthcare</sdc:value><sdc:value sdc:p="4">segment and Animal Health segment. The company was founded</sdc:value><sdc:value sdc:p="5">in 1849.</sdc:value></sdc:g_business><sdc:g_business1><sdc:value>Pfizer Inc, headquartered in New York, New York, manufactures and wholesales prescription medicines and other pharmaceuticals for humans and animals. The Group operates in three segments: Human Health segment, Consumer Healthcare segment and Animal Health segment. The company was founded in 1849.</sdc:value></sdc:g_business1><sdc:h_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value><sdc:value sdc:p="5">6.00000</sdc:value><sdc:value sdc:p="6">7.00000</sdc:value><sdc:value sdc:p="7">8.00000</sdc:value><sdc:value sdc:p="8">9.00000</sdc:value><sdc:value sdc:p="9">10.00000</sdc:value><sdc:value sdc:p="10">11.00000</sdc:value><sdc:value sdc:p="11">12.00000</sdc:value><sdc:value sdc:p="12">13.00000</sdc:value></sdc:h_SEQ><sdc:h_TEST><sdc:value sdc:p="0">Tianjin Tianyao Pharmaceutical</sdc:value><sdc:value sdc:p="1">Co Ltd, located in Tianjin,</sdc:value><sdc:value sdc:p="2">China, manufactures,</sdc:value><sdc:value sdc:p="3">wholesales and exports raw</sdc:value><sdc:value sdc:p="4">material medicines, small</sdc:value><sdc:value sdc:p="5">capacity injections and</sdc:value><sdc:value sdc:p="6">medicinal preparations. Major</sdc:value><sdc:value sdc:p="7">products include</sdc:value><sdc:value sdc:p="8">corticosteroids and</sdc:value><sdc:value sdc:p="9">cardiovascular medicine,</sdc:value><sdc:value sdc:p="10">dexamethasone, cortisone</sdc:value><sdc:value sdc:p="11">acetate and others. The</sdc:value><sdc:value sdc:p="12">company was founded in 1999.</sdc:value></sdc:h_TEST><sdc:h_business><sdc:value sdc:p="0">Tianjin Tianyao Pharmaceutical Co Ltd, located in Tianjin,</sdc:value><sdc:value sdc:p="1">China, manufactures, wholesales and exports raw material</sdc:value><sdc:value sdc:p="2">medicines, small capacity injections and medicinal</sdc:value><sdc:value sdc:p="3">preparations. Major products include corticosteroids and</sdc:value><sdc:value sdc:p="4">cardiovascular medicine, dexamethasone, cortisone acetate</sdc:value><sdc:value sdc:p="5">and others. The company was founded in 1999.</sdc:value></sdc:h_business><sdc:h_business1><sdc:value>Tianjin Tianyao Pharmaceutical Co Ltd, located in Tianjin, China, manufactures, wholesales and exports raw material medicines, small capacity injections and medicinal preparations. Major products include corticosteroids and cardiovascular medicine, dexamethasone, cortisone acetate and others. The company was founded in 1999.</sdc:value></sdc:h_business1><sdc:i_AFEEPCT><sdc:value>0.00000</sdc:value></sdc:i_AFEEPCT><sdc:i_AFEETOT><sdc:value>0.00000</sdc:value></sdc:i_AFEETOT><sdc:i_ATERMFEE><sdc:value>0.00000</sdc:value></sdc:i_ATERMFEE><sdc:i_COMOUT><sdc:value>542.89000</sdc:value></sdc:i_COMOUT><sdc:i_CROSS1><sdc:value>Y</sdc:value></sdc:i_CROSS1><sdc:i_DATEANN><sdc:value>17 Jun 08</sdc:value></sdc:i_DATEANN><sdc:i_DATEANN2><sdc:value>Tue, 17 Jun 2008 00:00:00 EST</sdc:value></sdc:i_DATEANN2><sdc:i_DATEANNS><sdc:value>Date Announced: 06/17/2008</sdc:value></sdc:i_DATEANNS><sdc:i_DATEEFFS><sdc:value>Date Effective:</sdc:value></sdc:i_DATEEFFS><sdc:i_DESCR><sdc:value>Merger</sdc:value></sdc:i_DESCR><sdc:i_DESCR1><sdc:value>Friendly</sdc:value></sdc:i_DESCR1><sdc:i_FEEPCT><sdc:value>0.00000</sdc:value></sdc:i_FEEPCT><sdc:i_FEETOT><sdc:value>0.00000</sdc:value></sdc:i_FEETOT><sdc:i_HOSTAFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTAFEETOT><sdc:i_HOSTENTVAL><sdc:value>0.00000</sdc:value></sdc:i_HOSTENTVAL><sdc:i_HOSTFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTFEETOT><sdc:i_HOSTPR><sdc:value>0.00000</sdc:value></sdc:i_HOSTPR><sdc:i_HOSTPRLABEL><sdc:value>Price/Share</sdc:value></sdc:i_HOSTPRLABEL><sdc:i_HOSTTFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTTFEETOT><sdc:i_HOSTVALUE><sdc:value>0</sdc:value></sdc:i_HOSTVALUE><sdc:i_HOSTVALUE1><sdc:value>0.00000</sdc:value></sdc:i_HOSTVALUE1><sdc:i_HOST_EQVAL><sdc:value>0.00000</sdc:value></sdc:i_HOST_EQVAL><sdc:i_HOST_RANKVAL><sdc:value>0</sdc:value></sdc:i_HOST_RANKVAL><sdc:i_HOST_RANKVAL1><sdc:value>0.00000</sdc:value></sdc:i_HOST_RANKVAL1><sdc:i_PCTACQ><sdc:value>0.00000</sdc:value></sdc:i_PCTACQ><sdc:i_PCTOWN><sdc:value>0.00000</sdc:value></sdc:i_PCTOWN><sdc:i_PR><sdc:value>0.00000</sdc:value></sdc:i_PR><sdc:i_PR_INITIAL><sdc:value>0.00000</sdc:value></sdc:i_PR_INITIAL><sdc:i_RANKVAL><sdc:value>0.00000</sdc:value></sdc:i_RANKVAL><sdc:i_RANK_HOSTRANKVAL><sdc:value>0</sdc:value></sdc:i_RANK_HOSTRANKVAL><sdc:i_RATE><sdc:value>0.00000</sdc:value></sdc:i_RATE><sdc:i_STATUS_MMC><sdc:value>N</sdc:value></sdc:i_STATUS_MMC><sdc:i_STGVAL><sdc:value>0.00000</sdc:value></sdc:i_STGVAL><sdc:i_TERMFEE><sdc:value>0.00000</sdc:value></sdc:i_TERMFEE><sdc:i_TFEEPCT><sdc:value>0.00000</sdc:value></sdc:i_TFEEPCT><sdc:i_TFEETOT><sdc:value>0.00000</sdc:value></sdc:i_TFEETOT><sdc:i_TTERMFEE><sdc:value>0.00000</sdc:value></sdc:i_TTERMFEE><sdc:i_VALLIA><sdc:value>0.00000</sdc:value></sdc:i_VALLIA><sdc:i_VALNOLIA><sdc:value>0.00000</sdc:value></sdc:i_VALNOLIA><sdc:i_VALUE><sdc:value>0.00000</sdc:value></sdc:i_VALUE><sdc:j_EQVALCF><sdc:value>0.00000</sdc:value></sdc:j_EQVALCF><sdc:j_EVCF><sdc:value>0.00000</sdc:value></sdc:j_EVCF><sdc:j_EVEBIT><sdc:value>0.00000</sdc:value></sdc:j_EVEBIT><sdc:j_EVNI><sdc:value>0.00000</sdc:value></sdc:j_EVNI><sdc:j_EVSALES><sdc:value>0.00000</sdc:value></sdc:j_EVSALES><sdc:j_MPRICEBOOK><sdc:value>0.00000</sdc:value></sdc:j_MPRICEBOOK><sdc:j_PHELD><sdc:value>0.00000</sdc:value></sdc:j_PHELD><sdc:j_PSOUGHT><sdc:value>100.00000</sdc:value></sdc:j_PSOUGHT><sdc:j_RANKVALCF><sdc:value>0.00000</sdc:value></sdc:j_RANKVALCF><sdc:j_RANKVALEB><sdc:value>0.00000</sdc:value></sdc:j_RANKVALEB><sdc:j_RANKVALNA><sdc:value>0.00000</sdc:value></sdc:j_RANKVALNA><sdc:j_RANKVALNI><sdc:value>0.00000</sdc:value></sdc:j_RANKVALNI><sdc:j_RANKVALSALES><sdc:value>0.00000</sdc:value></sdc:j_RANKVALSALES><sdc:j_VALEB><sdc:value>0.00000</sdc:value></sdc:j_VALEB><sdc:j_VALNI><sdc:value>0.00000</sdc:value></sdc:j_VALNI><sdc:j_VALSALES><sdc:value>0.00000</sdc:value></sdc:j_VALSALES><sdc:m_AMV><sdc:value>0.00000</sdc:value></sdc:m_AMV><sdc:m_CF3YGR><sdc:value>0.00000</sdc:value></sdc:m_CF3YGR><sdc:m_CF5YGR><sdc:value>0.00000</sdc:value></sdc:m_CF5YGR><sdc:m_DCR><sdc:value>0.00000</sdc:value></sdc:m_DCR><sdc:m_ENTVAL><sdc:value>0.00000</sdc:value></sdc:m_ENTVAL><sdc:m_EPS3YGR><sdc:value>0.00000</sdc:value></sdc:m_EPS3YGR><sdc:m_EPS5YGR><sdc:value>0.00000</sdc:value></sdc:m_EPS5YGR><sdc:m_LTD><sdc:value>0.00000</sdc:value></sdc:m_LTD><sdc:m_MV><sdc:value>0.00000</sdc:value></sdc:m_MV><sdc:m_NETASS><sdc:value>0.00000</sdc:value></sdc:m_NETASS><sdc:m_NETASS3YGR><sdc:value>0.00000</sdc:value></sdc:m_NETASS3YGR><sdc:m_NETASS5YGR><sdc:value>0.00000</sdc:value></sdc:m_NETASS5YGR><sdc:m_NI3YGR><sdc:value>0.00000</sdc:value></sdc:m_NI3YGR><sdc:m_NI5YGR><sdc:value>0.00000</sdc:value></sdc:m_NI5YGR><sdc:n_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value></sdc:n_SEQ><sdc:n_SYNOPSIS><sdc:value sdc:p="0">CHINA - Pfizer Inc planned to</sdc:value><sdc:value sdc:p="1">merge with Tianjin Tianyao</sdc:value><sdc:value sdc:p="2">Pharmaceutical Co Ltd, a</sdc:value><sdc:value sdc:p="3">pharmaceuticals manufacturer</sdc:value><sdc:value sdc:p="4">and wholesaler.</sdc:value></sdc:n_SYNOPSIS><sdc:n_synopsis2><sdc:value>CHINA - Pfizer Inc planned to merge with Tianjin Tianyao Pharmaceutical Co Ltd, a pharmaceuticals manufacturer and wholesaler.</sdc:value></sdc:n_synopsis2><sdc:n_synopsis3><sdc:value sdc:p="0">CHINA - Pfizer Inc planned to merge with Tianjin Tianyao Pharmaceutical Co Ltd, a</sdc:value><sdc:value sdc:p="1">pharmaceuticals manufacturer and wholesaler.</sdc:value></sdc:n_synopsis3><sdc:n_synopsis4><sdc:value>CHINA - Pfizer Inc planned to merge with Tianjin Tianyao Pharmaceutical Co Ltd, a pharmaceuticals manufacturer and wholesaler.</sdc:value></sdc:n_synopsis4><sdc:n_synopsis5><sdc:value>CHINA - Pfizer Inc planned to merge with Tianjin Tianyao Pharmaceutical Co Ltd, a pharmaceuticals manufacturer and wholesaler.</sdc:value></sdc:n_synopsis5><sdc:q_DESCR><sdc:value>Pending</sdc:value></sdc:q_DESCR><sdc:q_HOSTANETASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTANETASS><sdc:q_HOSTANILTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTANILTM><sdc:q_HOSTASALESLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTASALESLTM><sdc:q_HOSTATASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTATASS><sdc:q_HOSTBOOKVALUE><sdc:value>0.00000</sdc:value></sdc:q_HOSTBOOKVALUE><sdc:q_HOSTCASHFLOW><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW><sdc:q_HOSTCASHFLOW1><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW1><sdc:q_HOSTCASHFLOW2><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW2><sdc:q_HOSTCASHFLOW3><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW3><sdc:q_HOSTCASHFLOW4><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW4><sdc:q_HOSTCASHFLOW5><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW5><sdc:q_HOSTCOMMONEQUITY><sdc:value>0.00000</sdc:value></sdc:q_HOSTCOMMONEQUITY><sdc:q_HOSTEBITLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTEBITLTM><sdc:q_HOSTEPS1><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS1><sdc:q_HOSTEPS2><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS2><sdc:q_HOSTEPS3><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS3><sdc:q_HOSTEPS4><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS4><sdc:q_HOSTEPS5><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS5><sdc:q_HOSTEPSLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPSLTM><sdc:q_HOSTNETASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS><sdc:q_HOSTNETASS1><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS1><sdc:q_HOSTNETASS2><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS2><sdc:q_HOSTNETASS3><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS3><sdc:q_HOSTNETASS4><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS4><sdc:q_HOSTNETASS5><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS5><sdc:q_HOSTNI1><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI1><sdc:q_HOSTNI2><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI2><sdc:q_HOSTNI3><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI3><sdc:q_HOSTNI4><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI4><sdc:q_HOSTNI5><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI5><sdc:q_HOSTNILTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTNILTM><sdc:q_HOSTPTINC1><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC1><sdc:q_HOSTPTINC2><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC2><sdc:q_HOSTPTINC3><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC3><sdc:q_HOSTPTINC4><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC4><sdc:q_HOSTPTINC5><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC5><sdc:q_HOSTPTINCLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINCLTM><sdc:q_HOSTSALES1><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES1><sdc:q_HOSTSALES2><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES2><sdc:q_HOSTSALES3><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES3><sdc:q_HOSTSALES4><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES4><sdc:q_HOSTSALES5><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES5><sdc:q_HOSTSALESLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALESLTM><sdc:q_HOSTTASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS><sdc:q_HOSTTASS1><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS1><sdc:q_HOSTTASS2><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS2><sdc:q_HOSTTASS3><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS3><sdc:q_HOSTTASS4><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS4><sdc:q_HOSTTASS5><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS5><sdc:q_STATUS><sdc:value>Status:Pending</sdc:value></sdc:q_STATUS><sdc:r_PE><sdc:value>-999.00000</sdc:value></sdc:r_PE><sdc:r_PE_PRINT><sdc:value>np</sdc:value></sdc:r_PE_PRINT><sdc:r_PFTMARG><sdc:value>0.00000</sdc:value></sdc:r_PFTMARG><sdc:r_PRICEBOOK><sdc:value>-999.00000</sdc:value></sdc:r_PRICEBOOK><sdc:r_PRICEBOOK_PRINT><sdc:value>np</sdc:value></sdc:r_PRICEBOOK_PRINT><sdc:r_PTINC3YGR><sdc:value>0.00000</sdc:value></sdc:r_PTINC3YGR><sdc:r_PTINC5YGR><sdc:value>0.00000</sdc:value></sdc:r_PTINC5YGR><sdc:r_ROE><sdc:value>0.00000</sdc:value></sdc:r_ROE><sdc:r_SALES3YGR><sdc:value>0.00000</sdc:value></sdc:r_SALES3YGR><sdc:r_SALES5YGR><sdc:value>0.00000</sdc:value></sdc:r_SALES5YGR><sdc:r_SE><sdc:value>0.00000</sdc:value></sdc:r_SE><sdc:r_TASS3YGR><sdc:value>0.00000</sdc:value></sdc:r_TASS3YGR><sdc:r_TASS5YGR><sdc:value>0.00000</sdc:value></sdc:r_TASS5YGR><sdc:r_TTCFMULT><sdc:value>0.00000</sdc:value></sdc:r_TTCFMULT><sdc:r_TTEBITMULT><sdc:value>0.00000</sdc:value></sdc:r_TTEBITMULT><sdc:r_VALNA><sdc:value>0.00000</sdc:value></sdc:r_VALNA><sdc:sic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value><sdc:value sdc:p="3">5122:Drugs, drug proprietaries, and druggists' sundries</sdc:value></sdc:sic_SIC><sdc:upa_UPACIDGEN><sdc:value>11396001</sdc:value></sdc:upa_UPACIDGEN><sdc:upa1_EXCHANGE><sdc:value>New York</sdc:value></sdc:upa1_EXCHANGE><sdc:upa1_NATION><sdc:value>United States</sdc:value></sdc:upa1_NATION><sdc:upa1_SICP><sdc:value>2834</sdc:value></sdc:upa1_SICP><sdc:upa1_STATE><sdc:value>New York</sdc:value></sdc:upa1_STATE><sdc:upa1_STATUS><sdc:value>Public</sdc:value></sdc:upa1_STATUS><sdc:upa1_TICKER><sdc:value>PFE</sdc:value></sdc:upa1_TICKER><sdc:upsic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value><sdc:value sdc:p="3">5122:Drugs, drug proprietaries, and druggists' sundries</sdc:value></sdc:upsic_SIC><sdc:upt_UPTCIDGEN><sdc:value>727623002</sdc:value></sdc:upt_UPTCIDGEN><sdc:upt1_EXCHANGE><sdc:value>Shanghai</sdc:value></sdc:upt1_EXCHANGE><sdc:upt1_NATION><sdc:value>China</sdc:value></sdc:upt1_NATION><sdc:upt1_SICP><sdc:value>2834</sdc:value></sdc:upt1_SICP><sdc:upt1_STATE><sdc:value>Foreign</sdc:value></sdc:upt1_STATE><sdc:upt1_STATUS><sdc:value>Public</sdc:value></sdc:upt1_STATUS><sdc:upt1_TICKER><sdc:value>600488</sdc:value></sdc:upt1_TICKER><sdc:x_RANK1_VALUE><sdc:value>0.00000</sdc:value></sdc:x_RANK1_VALUE><sdc:x_RANK_HOSTRANKVAL><sdc:value>0.00000</sdc:value></sdc:x_RANK_HOSTRANKVAL><sdc:x_RANK_RANKVAL><sdc:value>0.00000</sdc:value></sdc:x_RANK_RANKVAL><sdc:x_rank_rankstgval><sdc:value>0.00000</sdc:value></sdc:x_rank_rankstgval></sdc:deal><category>Deal Information</category><alacra:ip>Thomson Financial Mergers &amp; Acquisitions</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/HIN-0001-26076967</link><guid isPermaLink="false">newstex/HIN-0001-26076967</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> Jun. ##, #### (The Hindu Business Line delivered by Newstex) --     Our Bureau   Chennai, June ##  Trading volumes volume improved marginally to Rs ##,###.## crore against TuesdayaÂ€Â™s turnover of about ##,### crore. Nifty June future...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04009000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04009004</newstex:cat><pubDate>6/18/2008 5:06:34 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18003000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">The Hindu Business Line</newstex:Publication><title>Fresh accumulations in Ranbaxy</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">HIN-0001-26076967</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PFIZER INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">RELIANCE PETROLEUM LTD</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">TATA STEEL LTD</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PFE</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">RPLUF</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">TAELF</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item></channel></rss>